• June 16-19, 2025
  • Boston Convention & Exhibition Center

Biotech Beyond Borders: Emerging Stronger from a Complex Macroenvironment

Loading

Biotech Beyond Borders: Emerging Stronger from a Complex Macroenvironment

Monday, June 03, 2024
Breakout Session
Business Development and Finance
32AB
The 34th edition of EY’s Beyond Borders Biotechnology Report provides an in-depth quantitative and qualitative look at the US and European biotechnology industry’s standing within a complex financing, regulatory and fast evolving healthcare environment. Despite a near closure of the IPO window and a difficult venture capital raising landscape following the sugar high during the pandemic, the start-up innovation engine of the pharmaceutical ecosystem continues to produce novel treatments. Biotech’s are advancing novel molecular entities – many enabled by new technologies such as cell and gene therapies, mRNA, Antibody-Drug Conjugates (ADC), CAR-T, while using generative AI/ML to create efficiencies in the process. We will explore these current topics – and more – during the Beyond Borders session.
Speakers
Arda Ural, PhD
Americas Life Sciences Sector Leader
EY (Ernst & Young)
Speakers
Brian Bronk, PhD
Head of Business Development, Neurology, Rare Diseases, Technology Platforms and R&D Transactions Partnering
Sanofi
Chris Garabedian
VC Portfolio Manager
Perceptive Advisors
Julie Rozenblyum
Senior Vice President, Business Development
BMS
Barbara Ryan
Board Member, Senior Advisor to EY, Indivior, Mink, Invo, SafeCor Pharmaceutical Companies
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS